Related Experiment Videos
[Morbidity among patients with clinically localized prostatic cancer. A registry-based case-control study]
1H:S Rigshospitalet, urologisk afdeling D, abdominalcentret, Kraeftens Bekaempelse, institut for epidemiologisk kraeftforskning.
Ugeskrift for Laeger
|October 23, 2001
Summary
Patients diagnosed with localized prostate cancer experience significantly higher morbidity and healthcare costs compared to the general population. This excess morbidity, particularly in the years following diagnosis, highlights potential areas for intervention and cost reduction.
Area of Science:
- Oncology
- Health Services Research
- Epidemiology
Background:
- Expectant management was the standard approach for localized prostate cancer in Denmark.
- Recent shifts in strategy necessitate understanding the patient's morbidity burden.
Purpose of the Study:
- To compare the morbidity of localized prostate cancer patients with an age-matched general population.
- To evaluate the excess healthcare utilization and costs associated with prostate cancer diagnosis.
Main Methods:
- A historical, prospective, case-control study design.
- Inclusion of 4744 patients aged 74 or younger with newly diagnosed localized prostate cancer.
- Comparison of patient morbidity and hospital costs against a matched background population.
Main Results:
- Patients with localized prostate cancer exhibited significantly higher morbidity.
- Hospital admission rates were substantially elevated in the year of diagnosis (6.7x) and subsequent years (2.7x).
- Hospital care costs for prostate cancer patients significantly exceeded those of the control group.
Conclusions:
- Newly diagnosed localized prostate cancer is associated with significant patient morbidity.
- A notable excess morbidity exists compared to age-matched controls.
- Opportunities to reduce patient morbidity and associated healthcare costs warrant further investigation.